Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Monitoring Immune Function in the Allogeneic Transplant Recipient: Predicting Graft vs Host Disease (GvHD) and Infection.

Elias J. Anaissie, MD, Jose A. Diaz, MD, Monica L. Grazziutti, MD, Marisa H. Miceli, MD, Michele Fox-Cottler, MD, Bart Barlogie, MD, Frits van Rhee, MD

Blood (2007) 110 (11): 1966.

https://doi.org/10.1182/blood.V110.11.1966.1966

Published: 2007

Journal Articles

Predicting Response to Therapy for Graft-vs-Host Disease (GvHD) with a Rapid Immune Function Assay.

Elias J. Anaissie, MD, Jose A. Diaz, MD, Monica L. Grazziutti, MD, Marisa H. Miceli, MD, Michele Fox-Cottler, MD, Bart Barlogie, MD, Frits van Rhee, MD

Blood (2007) 110 (11): 5012.

https://doi.org/10.1182/blood.V110.11.5012.5012

Published: 2007

Journal Articles

Outcome of Invasive Aspergillosis (IA) in 30 Patients with Hematological Cancer (Hem-Ca): Immunity Is (Almost) Everything.

Marisa H. Miceli, MD, Monica L. Grazziutti, MD, Gail L. Woods, MD, Jose A. Diaz, MD, Somashekar G. Krishna, MD, Elias N. Kiwan, MD, Nayyar Syed, MD, Bart Barlogie, MD, PHD, Elias J. Anaissie, MD

Blood (2006) 108 (11): 5314.

https://doi.org/10.1182/blood.V108.11.5314.5314

Published: 2006

Journal Articles

Predicting Risk of Infection and Graft vs. Host Disease (GvHD), and Response to Immunosuppression (ISP) in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Patients (pts) Using the Cylex®ImmuKnow® Assay: A Pilot Study.

Elias J. Anaissie, Jose A. Diaz, Monica L. Grazziutti, Marisa H. Miceli, Michele Fox-Cottler, Bart Barlogie

Blood (2006) 108 (11): 5325.

https://doi.org/10.1182/blood.V108.11.5325.5325

Published: 2006

Journal Articles

Daily C - Reactive Protein (CRP) Levels Allow Early Identification of Patients with Severe Complications after Melphalan (MEL) and Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM).

Elias J. Anaissie, MD, Monica L. Grazziutti, MD, Athanasios Fassas, MD, Li Dong, MD, Miceli H. Miceli, MD, Frits Van Rhee, MD, PhD, Klaus A. Hollmig, MD, Giampaolo Talamo, MD, Guido J. Tricot, MD, Bart Barlogie, MD

Blood (2004) 104 (11): 5040.

https://doi.org/10.1182/blood.V104.11.5040.5040

Published: 2004

Journal Articles

Increased Bone Marrow Iron Stores, Severe Mucositis and Large Area under the Curve (AUC) of Profound Neutropenia Predict Severe Infection in 382 Myeloma Patients Undergoing Melphalan - Autologous Stem Cell Transplantation (MEL-ASCT).

Elias J. Anaissie, MD, Marisa H. Miceli, MD, Li Dong, MD,MS, Monica L. Grazziutti, MD, Sabitha Rajan, Giampaolo Talamo, MD, Raymond Thertulien, MD, PhD, Anasthasios Fassas, MD, Guido Tricot, MD, Bart Barlogie, MD, PhD

Blood (2004) 104 (11): 1158.

https://doi.org/10.1182/blood.V104.11.1158.1158

Published: 2004

Journal Articles

The Conventional Body Surface Area (BSA) Method of Calculating the Dose of Melphalan (MEL) Results in Widely Variable MEL Exposure and Mucositis Risk in Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplantation (ASCT).

Elias J. Anaissie, MD, Monica L. Grazziutti, MD, Dong Li, MD, MS, Marisa H. Miceli, MD, Athanasios Fassas, MD, Raymond Thertulien, MD, PhD, Sabitha Rajan, Fariba Saghafifar, MD, Guido J. Tricot, MD, Bart Barlogie, MD

Blood (2004) 104 (11): 1159.

https://doi.org/10.1182/blood.V104.11.1159.1159

Published: 2004

NARROW

Monitoring Immune Function in the Allogeneic Transplant Recipient: Predicting Graft vs Host Disease (GvHD) and Infection.

Predicting Response to Therapy for Graft-vs-Host Disease (GvHD) with a Rapid Immune Function Assay.

Outcome of Invasive Aspergillosis (IA) in 30 Patients with Hematological Cancer (Hem-Ca): Immunity Is (Almost) Everything.

Predicting Risk of Infection and Graft vs. Host Disease (GvHD), and Response to Immunosuppression (ISP) in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Patients (pts) Using the Cylex®ImmuKnow® Assay: A Pilot Study.

Daily C - Reactive Protein (CRP) Levels Allow Early Identification of Patients with Severe Complications after Melphalan (MEL) and Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM).

Increased Bone Marrow Iron Stores, Severe Mucositis and Large Area under the Curve (AUC) of Profound Neutropenia Predict Severe Infection in 382 Myeloma Patients Undergoing Melphalan - Autologous Stem Cell Transplantation (MEL-ASCT).

The Conventional Body Surface Area (BSA) Method of Calculating the Dose of Melphalan (MEL) Results in Widely Variable MEL Exposure and Mucositis Risk in Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplantation (ASCT).

Email alerts

ASH Publications

American Society of Hematology

Monitoring Immune Function in the Allogeneic Transplant Recipient: Predicting Graft vs Host Disease (GvHD) and Infection.

Predicting Response to Therapy for Graft-vs-Host Disease (GvHD) with a Rapid Immune Function Assay.

Outcome of Invasive Aspergillosis (IA) in 30 Patients with Hematological Cancer (Hem-Ca): Immunity Is (Almost) Everything.

Predicting Risk of Infection and Graft vs. Host Disease (GvHD), and Response to Immunosuppression (ISP) in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Patients (pts) Using the Cylex®ImmuKnow® Assay: A Pilot Study.

Daily C - Reactive Protein (CRP) Levels Allow Early Identification of Patients with Severe Complications after Melphalan (MEL) and Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM).

Increased Bone Marrow Iron Stores, Severe Mucositis and Large Area under the Curve (AUC) of Profound Neutropenia Predict Severe Infection in 382 Myeloma Patients Undergoing Melphalan - Autologous Stem Cell Transplantation (MEL-ASCT).

The Conventional Body Surface Area (BSA) Method of Calculating the Dose of Melphalan (MEL) Results in Widely Variable MEL Exposure and Mucositis Risk in Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplantation (ASCT).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only